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Abstract: The aim of the present review is underline the association between cardiac diseases and anxiety and depression. 
In the first part of the article, there is a description of anxiety and depression from the definitions of DSM-IV TR. In the 
second part, the authors present the available tests and questionnaires to assess depression and anxiety in patients with 
cardiovascular disease. In the last part of the review different types of interventions are reported and compared; available 
interventions are pharmacological or psychological treatments. 
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INTRODUCTION 
It is known that in patients with ischemic heart disease, 
anxiety and depression are predictive of adverse short- and 
long-term outcomes [1, 2]. In fact, patients who have anxiety 
or depression during hospital admission are at increased risk 
for higher rates of in-hospital complications such as recur-
rent ischemia, re-infarction and malignant arrhythmias [3, 4]. 
They also suffer higher mortality and re-infarction rates 
months to years after their initial cardiac event [4-7]. Anxi-
ety disorders and depression are among the most prevalent 
psychiatric disorders [8]. Given the prevalence of anxiety 
and depression in the general population and in patients with 
Coronary Heart Disease [CHD], the potential public health 
impact for preventing the development and progression of 
CHD by appreciating the nature of the relationship between 
anxiety, depression and CHD is enormous [9]. Thus, it is 
clinically relevant in patient with cardiovascular disease to 
assess the psychological profile and treat emotional condi-
tions that confer an increase risk of major adverse cardiovas-
cular events. 
ANXIETY AND DEPRESSION 
Anxiety is a negative affective state resulting from an in-
dividual’s perception of threat and characterized by a per-
ceived inability to predict, control or gain the preferred re-
sults in given situations [10]. Several studies suggest a rela-
tionship between anxiety disorders and increased cardiac 
outcomes [11]. Anxiety seemed to be an independent risk 
factor for incident CHD and cardiac mortality. Anxiety   
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seemed to be an independent risk factor for incident CHD 
and cardiac mortality. The most recent meta-analysis [12] of 
references [1980 to 2009] on prospective studies of nonpsy-
chiatric cohorts of initially healthy persons, in which anxiety 
was assessed at baseline, has shown as anxious persons were 
at risk of CHD [hazard ratio 1.26] and cardiac death [hazard 
ratio: 1.48], independently by demographic variables, bio-
logical risk factors, and health behaviors. In a much larger 
study [13], in subjects with no prior history of CHD, a dose-
response relationship was found between phobic anxiety and 
coronary heart disease mortality [relative risk 2.5, 95% con-
fidence interval 1.00 to 5.96]. Patients who are too anxious 
frequently are unable to learn or act upon new information 
about necessary life-style changes [14]. Moreover a recent 
Swedish 37years longitudinal study [4] which have investi-
gated the long-term cardiac effects of depression and anxiety 
assessed at young age [18-20 years] according to Interna-
tional Classification of Diseases-8th Revision [ICD-8] crite-
ria has been shown as anxiety is an independently predicted 
subsequent CHD events. Observations have shown a hazard 
ratios associated with anxiety of 2.17 and 2.51 for CHD and 
for acute myocardial infarction, respectively, against a corre-
sponding hazard ratios associated with depression of 1.04 
and 1.03. More recently the study by Zafar et al. [15] has 
examined, by a cross-sectional method, the effects of both 
depression and anxiety on platelet reactivity in a patient 
population with stable coronary artery disease. Findings 
show as subjects who were both depressed and anxious had 
significantly higher serotonin-mediated platelet aggregation 
compared with depressed-only subjects and subjects without 
affective symptoms. Anxiety and the mental stress associated 
with it contribute to excessive SNS activation and catecho-
lamine release [16]. The bidirectional association between 
mood disorders and heart disease is multifaceted, involving 
an integration of several central and peripheral processes. On Clinical Psychology and Cardiovascular Disease  Clinical Practice & Epidemiology in Mental Health, 2011, Volume 7     149 
the base of the whole these data Wittstein [17] hypothesizes 
potential mechanisms of biological pathways between anxi-
ety and serotonin to enhanced platelet activation. As indi-
cated by DSM-TR [18] depression is a clinical syndrome 
defined by the presence of five out of nine follow criteria 
during the same 2-week period: depressed mood, diminished 
interest or pleasure in daily activities, significant uninten-
tional weight change, sleep disturbance, psychomotor retar-
dation or agitation, fatigue or loss of energy, feelings of 
worthlessness or excessive/inappropriate guilt, decreased 
ability to concentrate, and thoughts of death or suicide. De-
pression is associated with a odd ratio of 2 to 7 fold elevated 
risk of subsequent cardiac events, which is comparable to 
traditional cardiovascular risk factors such as hypertension 
[19- 22] and this require a particular attention for the diagno-
sis.  
The diagnostic difficulty of the depression in cardiac pa-
tient is due to atypical clinical presentation of depression in 
this patients and this explains the elevated percentage under-
diagnosis of depression among cardiac patients. In 2008 the 
American Heart Association recommended [and the Ameri-
can Psychiatric Association endorsed] that “screening tests 
for depressive symptoms should be applied to identify pa-
tients who may require further assessment and treatment” if 
appropriate referral for further depression assessment and 
treatment is available. Depressive symptom dimensions after 
myocardial infarction [MI] may be differently related to 
prognosis. Somatic/affective [e.g., fatigue, sleep problems, 
and poor appetite] dimensions appear to be associated with a 
worse cardiac outcome than cognitive/affective dimensions 
[e.g., shame, guilt and negative self-image]. Specifically 
somatic/affective symptoms of depression [odds ratio: 1.49] 
it has been observed [23] to be related to a higher Killip class 
and mortality during the follow-up [12 months] period [odds 
ratio: 1.92]. These findings, which are in concordance with 
earlier studies [24-26], put further light on possible behav-
ioral pathways which could explain the relationship between 
depressive symptoms and prognosis in ACS patients via un-
healthy behavior, like smoking, less compliance, unhealthy 
diet and inactivity [27] and lack of physical activity [28]. 
ASSESSMENT OF ANXIETY AND DEPRESSION  
Recently the American Heart Association [AHA], the 
American College of Cardiology, and the American College 
of Physicians highlight the need to adopt validated and easily 
performed screening test for depressions and anxiety in pa-
tients with cardiovascular disease [29, 30]. 
Physicians have to be acknowledge that the psychologi-
cal risk is not uniform across all patients and that psycho-
logical factors might cluster together within individuals [31]. 
Currently, these individual differences are largely ignored in 
clinical research and practice, but they could be assessed 
with brief and standardized self-report measures and would 
do away with a single risk factor approach [32]. 
The Beck Depression Inventory [33, 34] is a self-report 
measure has 21 items grouped by diagnostic symptom [e.g., 
feelings of guilt, sadness, self-confidence and discourage-
ment, loss of interest, crying, changes in appetite, sleep diffi-
culties, suicidal ideation]. A cut-off score of 10 or greater 
identify the presence of depression. Scores at or above 10 are 
associated with poorer prognosis, whether for CHD progres-
sion [35] or “hard” medical endpoints such as death or myo-
cardial infarction [36, 37]. Other symptom-based measure of 
depression used in cardiac patients are the Centers for Epi-
demiological Studies-Depression [CES-D] scale [38, 39], 
and the Hospital Anxiety and Depression Scale [40]. To spe-
cifically assess exhaustion, the Maastricht Questionnaire can 
be used [41]. Also is available The Patient Health Question-
naire. The PHQ-9 is a nine-item tool, easy to administer and 
score. It has been well studied in both screening for and fol-
low-up of depression in primary care [42, 43]. The PHQ-2 
consists of the two first questions of the PHQ-9, which deal 
with mood and lack of pleasure. A cut-off score of 3 or 
higher has a sensitivity of 83% and a specificity of 92% [44], 
fulfilling the need for a quick and reliable depression screen-
ing tool. The clinician can also ask for a yes-or-no answer to 
the two questions of the PHQ-2. A yes to either of the two 
questions is up to 90% sensitive and 75% specific [43, 45]. 
Structured interviews are superior to questionnaires in dif-
ferentiating dysthymia from Minor Depression. Based on the 
DSM- IV TR criteria, structured interviews have been devel-
oped to assess depression as Structured Clinical Interview 
for DSM-IV TR Axis I Disorders [SCID] and others [for 
review see [46]].  
Patients with Acute coronary Syndrome [ACS] have 
many difficulties to emotional tolerate lengthy interviews 
specifically during the initial brief hospital stays. For this 
patients are indicated flexible clinical interviews conducted 
using an expressive-supportive method [47]. The Diagnostic 
Interview and Structured Hamilton [DISH] incorporates 
elements of other diagnostic and severity measures of de-
pression, and is well suited for use with this population. It 
allows to establishment of an work alliance by discussing 
patient’s emotional experiences. The DISH scoring takes 
into account symptom severity and duration [46]. 
The American Heart Association [AHA] [48] released a 
consensus document recommending that health care provid-
ers screen for and treat depression and anxiety in patients 
with coronary heart disease. Also Pozuelo and colleagues 
[49] recommend that clinicians systematically screen for it in 
their heart patients, in view of the benefits of antidepressant 
therapy. Pozuelo and colleagues think that clinicians should 
routinely screen for depression in cardiac patients and should 
not hesitate to treat it and eligible patients should routinely 
be referred to cardiac rehabilitation programs [49]. 
As commented by Dimsdale [50] the recent observations 
on anxiety come at a time when psychiatry is once again 
redrawing diagnostic guidelines in the Diagnostic and Statis-
tical Manual. To evaluate anxiety, simple screening ques-
tionnaires that have high reliability and validity are available. 
The Beck Anxiety Inventory [51], the Zung Self-Rating 
Anxiety Scale [52], or Hamilton Anxiety Scale [53] can be 
used as part of the routine workup of every patient. The 
Hamilton Anxiety Scale has the advantage of diagnosing 
depression as well as anxiety [53]. The major disadvantages 
in using the above scales are the time required for admini-
stration [15–25 minutes as part of a full battery], the need for 
scoring, and significant cost to purchase [29].  
A newly useful created instrument, the Psychological 
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cifically for the outpatient cardiology setting [54- 56] (see 
Table 1). This is a brief 6-item self-report measure that takes 
only minutes to perform and is highly correlated with other 
common scales and screens for anxiety, depressed mood, 
positive well-being, self-control, general health and vitality. 
The PGWBI score has shown to statistically be also corre-
lated with cardiac rehabilitation outcome [56]. 
The advantage of the PGWBI-6 is that only 1 scale is re-
quired to screen for all of these risk factors, and it can be 
filled out easily by the patient as part of the initial work up. 
The results can be quickly analyzed by a nurse or the cardi-
ologist and is available for no charge. These scales provide 
data that can quickly lead to treatment decisions regarding 
mental health care. The screening can serve to delineate 
Table 1. The Psychological General Well-Being Index [PGWBI-S] [29] 
1. Have you been bothered by nervousness or your "nerves" during the past month? 
Extremely so – to the point where I could not work or take care of things  0 
Very much so  1 
Quite a bit  2 
Some – enough to bother me  3 
A little  4 
Not at all  5 
2. How much energy, pep, or vitality did you have or feel during the past month? 
Very full of energy – lots of pep  5 
Fairly energetic most of the time  4 
My energy level varied quite a bit  3 
Generally low in energy or pep  2 
Very low in energy or pep most of the time  1 
No energy or pep at all – I fell drained, sapped  0 
3. I felt downhearted and blue during the past month. 
None of this time   5 
A little of the time  4 
Some of the time   3 
A good bit of the time  2 
Most of the time  1 
All of the time  0 
4. I was emotionally stable and sure of myself during the past month. 
None of the time  0 
A little of the time  1 
Some of the time  2 
A good bit of the time  3 
Most of the time  4 
All of the time  5 
5. I felt cheerful, lighthearted during the past month. 
None of the time  0 
A little of the time  1 
Some of the time  2 
A good bit of the time  3 
Most of the time  4 
All of the time  5 
6. I felt tired, worn out, used up, or exhausted during the past month. 
None of the time  5 
A little of the time  4 
Some of the time  3 
A good bit of the time  2 
Most of the time  1 
All of the time  0 Clinical Psychology and Cardiovascular Disease  Clinical Practice & Epidemiology in Mental Health, 2011, Volume 7     151 
normal levels of anxiety and depression from more patho-
logic levels [29]. 
Because anxiety can have neurobiologic, behavioral, and 
cognitive/psychologic correlates, it is imperative that cardi-
ologists accurately elicit symptoms of anxiety in the history 
and via screening that draw upon these 3 domains. The 
treatment of depression is articulated in three phases: 1) 
acute phase; purpose: to reduce symptoms [6-12 weeks]; 2) 
continuation phase; purpose: prevent relapse [4-9 months]; 




Pharmacological treatment of depression in patients with 
CHD is complex and entails certain limitations and contrain-
dications [47]. Table 2 shows the clinical trials of depression 
therapy in patient with cardiac diseases. 
Selective serotonin reuptake inhibitors [SSRI] tend to be 
tolerated better than the traditional tricyclic antidepressants 
[TCA] [58]. SSRIs have been found effective for treating 
depression in this population [61]. However, most SSRIs 
should not be used in combination with class IC anti-
arrhythmics and may also potentiate the effects of beta-
adrenergic blocking agents. Furthermore, SSRIs appear to 
reduce depressive symptoms but depression tends not to 
completely remit in patients with CAD [Coronary Artery 
disease]. The Myocardial Infarction Depression Intervention 
Trial [MIND-IT] [64] looked at whether the antidepressant 
mirtazapine [Remeron] would improve long-term depression 
and cardiovascular outcomes in depressed post-MI patients. 
In 18 months of follow-up, neither objective was obtained. 
The Cardiac Randomized Evaluation of Antidepressant and 
Psychotherapy Efficacy [CREATE] trial [63] tested the effi-
cacy of the SSRI citalopram [Celexa] and interpersonal ther-
apy in a short-term intervention. Here, the antidepressant 
was superior to placebo in the primary outcome of treating 
depression, but interpersonal therapy had no advantage over 
“clinical management,” ie, a shorter, 20-minute supportive 
intervention [49]. 
Psychological Interventions 
Cognitive behavioral therapy is often successfully used in 
the treatment of depressive disorders [47]. The main goal of 
this approach is to modify dysfunctional thoughts and emo-
tions by structured and empathic questioning of patients’ 
perceptions and thought processes [60]. The typical duration 
of psychological interventions in CAD patients ranges from 
8 to 12 weeks [65- 68]. Sebregts and colleagues [69] in-
tended to develop a relatively short intervention program of 
8 weeks, accessible for a large group of AMI [Acute myo-
cardial infarction] and coronary artery bypass grafting 
[CABG] patients. This intervention explicitly addressed mul-
tiple modifiable risk factors. It was directed at the reduction 
of psychological stress/distress [Type A behavior in particu-
lar], the reduction of excessive consumption of dietary fat, 
elevated serum cholesterol, lack of physical exercise, and 
although less explicitly—smoking and insufficient social 
support through the involvement of the patients’ partners in 
the intervention [68]. The results of this study show that 
Type A behavior can be reduced in coronary patients through 
a relatively short intervention program aimed at behavior 
change and risk reduction. Although No favorable effects 
were found on depression or vital exhaustion. In view of the 
findings on the diagnosis of depression, researchers do not 
unequivocally advise the intervention to the general popula-
tion of AMI and CABG patients [69]. Other behavioral 
medicine group programs have attempted to incorporate 
stress management, relaxation training/cognitive behavior 
therapy and lifestyle modification for heart disease including 
Ornish's Lifestyle Heart Trial [70, 71] and the Recurrent 
Coronary Prevention Project [72] for reducing Type-A be-
havior. In the case of the former, actual regression of coro-
nary artery stenosis was achieved in 1-year, and 4- and 5- 
year follow-up studies in those participants who maintained 
the lifestyle changes [73]. A recent study of an integrative 
Table 2. Clinical Trials of Depression Therapy in Patients with Cardiac Diseases 
Trial   Therapies  Treatment Period  Results 
M-HART 
[57] 
Home nursing intervention [vs usual care] 
for psychological distress 
1 year  Prognosis: no improvement 
 compared with usual care 
Roose and colleagues [58] 
and 
Nelson and colleagues [59] 
Nortriptyline vs paroxetine  6 weeks  Depression: both effective 
Drug safety: nortriptyline toxic 
ENRICHD 
[60] 
Cognitive behavior therapy vs usual  
medical care 
11 sessions over 6 
months 
Depression: cognitive behavior therapy modestly 
effective 
Prognosis: no difference vs usual care 
SADHART 
[61] 




Mirtazapine vs placebo  24 weeks  Depression: no difference vs placebo 
Prognosis: no difference vs placebo 
CREATE 
[63] 
Citalopram ± Interpersonal psychotherapy  12 weeks  Depression: 
citalopram effective; 
interpersonal psychotherapy not effective 152     Clinical Practice & Epidemiology in Mental Health, 2011, Volume 7  Compare et al. 
medicine approach applied to cardiac risk reduction demon-
strated that after 10 months of a personalized health plan 
consisting of mindfulness meditation, relaxation training, 
stress management, and health education and coaching, pa-
tients in the active treatment group had lowered risk, lost 
more weight, and exercised more frequently compared with 
the usual care group [74]. Overall behavioral medicine group 
programs have been shown to reduce the cost of unnecessary 
medical procedures and work-ups [especially related to anxi-
ety], improve complain with treatment, and reduce the risk 
factors of stress and an unhealthy lifestyle [75]. As well be-
cause these are group interventions this helps patients over-
come stigma, social isolation and learn how to better manage 
their anxiety and depression. 
Also for anxiety, cognitive behavior therapy, a well-
documented evidence-based treatment, should be instituted 
at the beginning of treatment to ensure that patients under-
stand their condition and that medication management is 
only one aspect of their treatment [76]. In cognitive behavior 
therapy, patients are taught to restructure anxiety-provoking 
thoughts leading to panic attacks, are taught relaxation tech-
niques to counteract stress and anxiety, and are given expo-
sure therapy to desensitize themselves to stressful stimuli. 
Cognitive behavior therapy is also extremely useful and ef-
fective in teaching anger management skills when treating 
Type A behavior pattern [TABP personality] [77]. Cognitive 
behavior therapy conveys the message to the patient that it is 
possible to learn self-management techniques and methods 
that will most likely allow them to discontinue medications 
within 6 months to 1 year. Other forms of psychotherapy, 
such as psychoanalytic, interpersonal, and supportive thera-
pies, can be effective as adjunctive therapies, but do not 
carry the wealth of evidence-based research demonstrating 
their effectiveness in the treatment of anxiety disorders.  
A new proposed anxiety and depression treatment algo-
rithm is based on PGWB initial screening (see Fig. (1)).  
As seen in the algorithm (see Fig. (1)), when the screen-
ing identifies patients who have more than mild anxiety and 
depression and have failed 1-2 medication trials, have suici-
dal or homicidal ideation or a history thereof, alco-
hol/substance abuse, mania or psychosis, history of sexual, 
physical abuse, or severe psychosocial distress, a referral 
should be made to a mental health professional. Integrating 
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ongoing assessments reduces the stigma of mental illness 
and leads to the greater likelihood of patients receiving ade-
quate mental health treatment. This strengthens the treatment 
alliance and can improve compliance with medical treat-
ment. 
Among the psychotherapies, cognitive behavior therapy 
[CBT] and interpersonal psychotherapy [IPT] are the most 
effective, in both acute and maintenance treatments [78]. 
Interpersonal psychotherapy is a time-limited [12-16 weekly 
1-hour sessions] manualized psychotherapy that was devel-
oped in the early 1970’s by Gerald Klerman and colleagues 
as a research intervention for outpatients with unipolar major 
depression [79]. Interpersonal psychotherapy is based on the 
presumption that interpersonal issues affect mood and mood 
impairs interpersonal functioning. Interpersonal psychother-
apy has been extensively researched and shown to be effec-
tive as both an acute and preventive treatment for major de-
pressive disorder [80]. IPT conceptualizes clinical depres-
sion as having three component processes: symptom forma-
tion caused by biological and/or psychological mechanisms; 
social functioning [involving, obviously, social interactions 
with others]; and enduring personality traits [81]. IPT inter-
venes in symptom formation and social dysfunction but does 
not address enduring personality traits in view of the time 
limits of treatment, the relatively low level of psychothera-
peutic intensity, the emphasis of treatment on the current 
depressive episode, and the difficulty in accurately evaluat-
ing personality in the midst of an Axis I disorder [82]. The 
brevity of the treatment imposes a structure that pressures 
the patient and therapist to work quickly to alleviate depres-
sive symptoms and resolve the current interpersonal crisis 
linked with the depression, thus discouraging the patient’s 
becoming dependent on the therapist [81]. For each patient, 
therapy focuses on one or, at most, two interpersonal prob-
lem areas that are identified as precursors of the current de-
pressive episode. These problem areas were derived from 
extensive research on the role of environmental influences 
on mood and are characterized as unresolved grief following 
the death of a loved one, role transitions [difficulty adjusting 
to changed life circumstances], interpersonal role disputes 
[conflicts with a significant other] and interpersonal deficits 
[impoverished social networks]. Maintaining the focus of 
treatment on a problematic interpersonal issue prevents the 
therapy from becoming too diffuse and forces the therapist 
and patient to discuss material that is relevant to the focal 
area and treatment objectives [81]. IPT also focuses on the 
“here and now,” that is, on current problematic interpersonal 
issues that are amenable to change, rather than on reconcil-
ing unresolved interpersonal problems having to do with the 
past. The focus on resolving current interpersonal problems 
and developing strategies for warding off future problems 
helps reduce the depressed patient’s tendency to ruminate 
about past events and experiences that cannot be changed 
and which only serve to reinforce the patient’s already low 
sense of self-esteem and dysphoria [81]. The primary goal of 
IPT is to obtain the remission of depressive symptoms by 
facilitating resolution of a current interpersonal crisis. At 
one-year follow-up, patients who received interpersonal psy-
chotherapy had better psychosocial functioning than those 
who did not receive this treatment [83]. The National Insti-
tute of Mental Health Treatment of Depression Collaborative 
Research Program [NIMH TDCRP] found that, in general, 
interpersonal psychotherapy is an effective monotherapy for 
patients with mild to moderate depression, but that antide-
pressant medication should be used as a first line treatment 
for severely ill patients. 
CONCLUSION 
Despite the large amount of evidence supporting signifi-
cant and independent associations between anxiety and de-
pression and the pathogenesis of cardiovascular disease, the 
2010 American College of Cardiology Foundation/Am-
erican Heart Association Guideline for Assessment of Car-
diovascular Risk in Asymptomatic Adults [84, 85] does not 
consider yet any of them. 
Further research is warranted to determine factors that 
may moderate anxiety in order to better understand the phe-
nomenon among acute myocardial infarction patients and 
develop effective interventions. It appears that anxiety after 
acute myocardial infarction is a universal phenomenon [9]. 
Future studies need to disentangle the cause effect relation-
ships between depression, anxiety and adverse health behav-
iors in patients with coronary artery disease [30]. As com-
mented on by Dimsdale [50] the recent findings regarding 
anxiety come at a time when psychiatry is once again re-
drawing diagnostic guidelines in the Diagnostic and Statisti-
cal Manual. For decades, the Diagnostic and Statistical Man-
ual has differentiated between anxiety disorders and depres-
sive disorders but in clinical practice these disorders rarely 
occur in isolation and the distress associated with them in-
creases synergistically when both sets of symptoms coexist. 
Future researches should analyze together the two symptoms 
and their synergic action in heart disease. It would be useful 
for clinical practice to develop treatments that combine 
strategies for anxiety and depression and evaluate whether 
such treatments would reduce cardiovascular risk [86].  
Depression can be treated effectively with a combination 
of psychological and pharmacological interventions [57]. 
Also anxiety is common among cardiac patients and should 
be treated to enhance recovery and decrease patients’ risk of 
subsequent cardiac events. One of the most important areas 
for future research is elucidating the mechanisms whereby 
anxiety causes poorer outcomes in acute myocardial infarc-
tion patients. The mechanisms [either physiological or be-
havioral] whereby anxiety is related to poorer short and long 
term outcomes in acute myocardial infarction patients have 
yet to be elucidated. Research in this area is important to 
help clinicians determine the best ways to manage acute 
myocardial infarction patients to decrease the negative im-
pact of anxiety [9]. 
In future trials, it is important to pay particular attention 
to nonresponders to intervention, because these patients have 
been shown to be at a higher risk of late mortality compared 
with responders [87]. If we are to continue lowering the rates 
of CHD, we have to continue to emphasize prevention of the 
modifiable risk factors. This will require that cardiologists, 
cardiovascular surgeons and mental health professionals 
work together to provide comprehensive treatments that ad-
dress not only CHD but optimize the mental health of pa-
tients. 154     Clinical Practice & Epidemiology in Mental Health, 2011, Volume 7  Compare et al. 
ABBREVIATIONS 
ACS =  Acute  coronary  Syndrome 
AMI  =  Acute myocardial infarction 
CABG  =  Coronary artery bypass grafting 
CAD  =  Coronary Artery disease 
CHD  =  Coronary Heart Disease 
DISH  =  Diagnostic Interview and Structured 
Hamilton 
ENRICHD  =  Enhancing Recovery in Coronary Heart 
Disease 
PGWBI  =  Psychological General Well Being Index 
PHQ  =  The Patient Health Questionnaire 
SSRI  =  Selective serotonin reuptake inhibitors 
TABP  =  Type A behavior pattern 
M-HART  =  The Montreal Heart Attack Readjust-
ment Trial 
ENRICHD  =  Enhancing Recovery in Coronary Heart 
Disease 
SADHART  =  Sertraline Antidepressant Heart Attack 
Randomized Trial 
MIND-IT  =  The Myocardial Infarction Depression 
Intervention Trial 
CREATE  =  The Cardiac Randomized Evaluation of 
Antidepressant and Psychotherapy   
Efficacy 
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